Background: Fluvastatin is an inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, effectively lowering serum cholesterol concentrations. A high-performance liquid chromatography (HPLC) assay was developed that determined the pharmacokinetics of fluvastatin in healthy individuals after administration of 40 and 80 mg fluvastatin.
Methods: The method was linear for serum concentrations between 10 ng/mL and 5,000 ng/mL, showing good coefficients of variations and sample stability. After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C,,4a), the time to reach CmaX (t.aJ, and the serum elimination half-life time were 528.5±8.8 ng/mL'h, 149.6 ±6.0 ng/mL, 60.0±30.0 minutes, and 108.0±7.9 minutes, respectively. The corresponding values for a dose of 80 mg fluvastatin were 1417.7 ±79.2 ng/mLh, 1024.7 +1085.1 ng/mL, 60.0 ±1.2 minutes, and 106.0 ±3.6 minutes, respectively. Doubling of the dose from 40 mg to 80 mg caused an overproportional increase of AUC and Cmax.
Results and Conclusion: Results suggest that the measurement of fluvastatin serum concentrations by means of HPLC provides reliable data within the broad range of physiological serum concentrations. The pharmacokinetic data after administration of high doses (80 mg) showed an overproportional increase of AUC and Cm,,, suggesting a saturation of the hepatic first-pass effect. Thus, in patients treated with additional substances interfering with fluvastatin metabolism, fluvastatin serum concentrations should be analyzed.
1. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs53:299-299, 1997
2.
2. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol81:582-582, 1998
3.
3. Lennernms H, Fager G. Pharmacodynamics and pharmaco-kinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet32:403-403, 1997
4.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet344:1383-1383, 1994
5.
5. Appel S, Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today32:39-39, 1996
6.
6. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet31:348-348, 1996
7.
7. Dain JG, Fu E, Gorski J, et al. Biotransformation of flu-vastatin sodium in humans. Drug Metab Dispos21:567-567, 1993
8.
8. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol46:49-49, 1998
9.
9. Lindahl A, Sandstrom R, Ungell AL, et al. Jejunal perme-ability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther60:493-493, 1996
10.
10. Sirtori CR. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther60:431-431, 1993
11.
11. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol50:209-209, 1996
12.
12. Kalafsky G, Smith HT, Choc MG. High-performance liquid chromatographic method for the determination of fluvastatin in human plasma. J Chromatogr614:307-307, 1993
13.
13. Toreson H, Eriksson BM. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. J Chromatogr729:13-13, 1996
14.
14. Toreson H, Eriksson BM. Liquid chromatographic determination of fluvastatin and its enantiomers in blood plasma by automated solid-phase extraction. Chromatographia45:29-29, 1997
15.
15. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (Fibrates). Clin Pharmacokinet34:155-155, 1998
16.
16. Schrama YC, Hene RJ, de Jonge N, et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients. Transplantation66:1175-1175, 1998
17.
17. Otter K, Mignat C. Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl708:235-235, 1998
18.
18. Siekmeier R, Marz W, GroB. Determination of pravastatin by high performance liquid chromatography. Int J Clin Pharmacol Ther38:419-419, 2000
19.
19. lacona I, Regazzi MB, Buggia I, et al. High-performance liquid chromatography determination of pravastatin in plasma. Ther Drug Monit16:191-191, 1994
20.
20. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol32:630-630, 1992
21.
21. Lennernas H. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?Pharm Res12:1573-1573, 1995
22.
22. Walter A, Gutknecht J. Permeability of small nonelectrolytes through lipid bilayer membranes. J Membr Biol90:207-207, 1986
23.
23. De Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther253:387-387, 1990
24.
24. Komai T, Tsujita Y. Hepatocyte selectivity of HMG-CoA reductase inhibitors. Drug News Perspect7:279-279, 1994
25.
25. Yamazaki M, Suzuki H, Hanano M, et al. Na(+)-independent mulitispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol264:G36-44, 1993
26.
26. Ziegler K, Hummelsiep S. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim Biophys Acta1153:23-23, 1993
